This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.
70 citations
,
February 2018 in “Seminars in Arthritis and Rheumatism” This study found that belimumab helped achieve low disease activity in over 40% of systemic lupus erythematosus patients in real-life settings, alongside reduced corticosteroid use and fewer flares.
87 citations
,
July 2012 in “Expert Review of Clinical Immunology” This review outlines pregnancy risks in systemic lupus erythematosus and emphasizes that active lupus nephritis at conception increases the risk of flares and poor obstetric outcomes; it reports no new clinical findings.
March 2025 in “Canadian dermatology today.” In this case series, treatment with clascoterone cream 1% was reported to be effective and well tolerated for diverse acne vulgaris patients, improving clinical outcomes whether used alone or in combination with other therapies, and addressing various other skin conditions.
This study reported that belimumab helped over 40% of active systemic lupus erythematosus patients achieve low disease activity, with more than 20% able to stop glucocorticoids completely.